RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients

Pancreatic ductal adenocarcinoma (PDAC) is characterized by early recurrence following pancreatectomy, rapid progression, and chemoresistance. Novel prognostic and predictive biomarkers are urgently needed to both stratify patients for clinical trials and select patients for adjuvant therapy regimen...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Muniz, Viviane P., Askeland, Ryan W., Zhang, Xuefeng, Reed, Sara M., Tompkins, Van S., Hagen, Jussara, McDowell, Bradley D., Button, Anna, Smith, Brian J., Weydert, Jamie A., Mezhir, James J., Quelle, Dawn E.
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2013
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3807645/
https://ncbi.nlm.nih.gov/pubmed/24167655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1947601913501074
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars